Bharat Biotech's indigenous COVID-19 vaccine 'COVAXIN' gets approval for phase I & II human clinical trials

The SARS-CoV-2 strain was isolated in NIV, Pune and transferred to Bharat Biotech. The indigenous inactivated vaccine was developed and manufactured in Bharat Biotech's BSL-3 (Bio-Safety Level 3) High Containment facility located in Genome Valley, Hyderabad.

from Latest News https://www.dnaindia.com/india/report-bharat-biotech-s-indigenous-covid-19-vaccine-covaxin-gets-approval-for-phase-i-ii-human-clinical-trials-2830185